Optimizing treatment in recurrent epithelial ovarian cancer.
about
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
P2860
Optimizing treatment in recurrent epithelial ovarian cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Optimizing treatment in recurrent epithelial ovarian cancer.
@en
Optimizing treatment in recurrent epithelial ovarian cancer.
@nl
type
label
Optimizing treatment in recurrent epithelial ovarian cancer.
@en
Optimizing treatment in recurrent epithelial ovarian cancer.
@nl
prefLabel
Optimizing treatment in recurrent epithelial ovarian cancer.
@en
Optimizing treatment in recurrent epithelial ovarian cancer.
@nl
P2093
P2860
P1476
Optimizing treatment in recurrent epithelial ovarian cancer.
@en
P2093
Eleonora Palluzzi
Gabriella Ferrandina
Giacomo Corrado
Giovanni Scambia
Maria Grazia Distefano
Vanda Salutari
P2860
P304
P356
10.1080/14737140.2017.1398088
P577
2017-10-31T00:00:00Z